| Index | — | P/E | — | EPS (ttm) | -1.96 | Insider Own | 30.95% | Shs Outstand | 47.23M | Perf Week | 0.41% |
| Market Cap | 932.87M | Forward P/E | — | EPS next Y | -0.55 | Insider Trans | -48.08% | Shs Float | 37.67M | Perf Month | 84.41% |
| Enterprise Value | 860.87M | PEG | — | EPS next Q | -0.11 | Short Float | 7.77% | Perf Quarter | 84.93% | ||
| Income | -89.00M | P/S | — | EPS this Y | — | Short Ratio | 2.40 | Perf Half Y | 177.00% | ||
| Sales | 1.00M | P/B | 24.55 | EPS next Y | — | ROA | -56.34% | Short Interest | 2.93M | Perf YTD | 224.84% |
| Book/sh | 0.80 | P/C | 12.96 | EPS next 5Y | — | ROE | -106.94% | 52W High | 19.86 -0.55% | Perf Year | 173.17% |
| Cash/sh | 1.52 | P/FCF | — | EPS past 3/5Y | — | ROIC | -71.25% | 52W Low | 4.19 371.36% | Perf 3Y | 172.04% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -61.84% -27.52% | Gross Margin | 51.00% | Volatility | 0.55% 3.63% | Perf 5Y | -14.13% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | -10880.25% | ATR (14) | 0.76 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 7.42 | Sales Y/Y TTM | -100.00% | Profit Margin | -9759.23% | RSI (14) | 78.90 | Recom | 2.60 |
| Dividend Gr. 3/5Y | — | Current Ratio | 7.42 | EPS Q/Q | 51.85% | SMA20 | 35.41% | Beta | 1.32 | Target Price | 20.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | 46.51% | Rel Volume | 0.22 | Prev Close | 19.80 |
| Employees | 88 | LT Debt/Eq | 0.00 | Earnings | Nov 05 | SMA200 | 118.09% | Avg Volume | 2.80M | Price | 19.75 |
| IPO Date | Sep 08, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -87.51% -88.26% | Net Debt/EBITDA | — | Volume | 621,425 | Change | -0.25% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-21-26 | Downgrade | HC Wainwright & Co. | Buy → Neutral | $20 |
| Oct-19-26 | Reiterated | Jefferies | $20 | |
| Jun-28-24 | Reiterated | Morgan Stanley | Overweight | $18 → $49 |
| Jun-28-24 | Reiterated | Chardan Capital | Buy | $29 → $55 |
| Mar-13-24 | Reiterated | BMO Capital | $67 | |
| Dec-09-22 | Reiterated | Morgan Stanley | Equal Weight | $18 |
| Nov-17-22 | Reiterated | Chardan Capital | Buy | $29 |
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1 | 43 | 25 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 12 | 10 | — | — | — | — | — | — | |
| Gross Profit | 0 | 31 | 15 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 22 | 27 | 21 | — | — | — | — | — | — | |
| Research and Development | 68 | 68 | 44 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -90 | -63 | -50 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1 | 19 | -1 | — | — | — | — | — | — | |
| Net Income Before Taxes | -89 | -44 | -50 | — | — | — | — | — | — | |
| Income Taxes | 0 | 1 | -7 | — | — | — | — | — | — | |
| Consolidated Net Income | -89 | -45 | -43 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -89 | -45 | -43 | — | — | — | — | — | — | |
| Net Income | -89 | -45 | -43 | — | — | — | — | — | — | |
| EPS (Recurring) | -5.67 | -2.37 | -3.48 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -5.67 | -2.37 | -3.48 | — | — | — | — | — | — | |
| EPS (Diluted) | -5.67 | -2.37 | -3.48 | — | — | — | — | — | — | |
| EBITDA | -88 | -49 | -50 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 97.28 | 2.40 | 8.34 | — | — | — | — | — | — | |
| Gross Margin | 0.00 | 72.09 | 60.00 | — | — | — | — | — | — | |
| Operating Margin | -9,000.00 | -146.51 | -200.00 | — | — | — | — | — | — | |
| Net Margin | -8,900.00 | -104.65 | -172.00 | — | — | — | — | — | — | |
| Shares Outstanding | 16 | 15 | 12 | — | — | — | — | — | — | |
| Market Capitalization | 97 | 103 | 208 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Griffiths Richard Ian | 10% Owner | Aug 10 '26 | Sale | 16.00 | 5,484,320 | 87,776,219 | 4,797,166 | Aug 13 |
| Griffiths Richard Ian | 10% Owner | Jul 06 '26 | Sale | 10.53 | 865,112 | 9,109,629 | 10,281,486 | Jul 07 |
| Griffiths Richard Ian | 10% Owner | Jul 02 '26 | Sale | 10.47 | 50,082 | 524,359 | 11,146,598 | Jul 07 |
| Griffiths Richard Ian | 10% Owner | Jul 01 '26 | Sale | 10.62 | 129,180 | 1,371,892 | 11,196,680 | Jul 07 |
| Griffiths Richard Ian | 10% Owner | Jun 30 '26 | Sale | 10.76 | 169,928 | 1,828,425 | 11,325,860 | Jul 07 |
| Griffiths Richard Ian | 10% Owner | Jun 29 '26 | Sale | 10.69 | 330,072 | 3,528,470 | 11,495,788 | Jul 07 |
| Griffiths Richard Ian | 10% Owner | Oct 27 '25 | Buy | 7.75 | 2,000 | 15,500 | 11,825,861 | Feb 13 |
| Griffiths Richard Ian | 10% Owner | Oct 27 '25 | Sale | 7.75 | 2,000 | 15,500 | 11,819,861 | Feb 13 |
| Griffiths Richard Ian | 10% Owner | Aug 03 '25 | Buy | 5.45 | 20,000 | 109,000 | 11,825,861 | Feb 13 |
| Griffiths Richard Ian | 10% Owner | Aug 03 '25 | Sale | 5.45 | 20,000 | 109,000 | 11,805,861 | Feb 13 |
| Griffiths Richard Ian | 10% Owner | Aug 01 '25 | Buy | 6.14 | 4,034 | 24,769 | 11,825,861 | Aug 04 |
| Griffiths Richard Ian | 10% Owner | Jul 31 '25 | Buy | 6.18 | 14,342 | 88,634 | 11,821,827 | Aug 04 |
| Griffiths Richard Ian | 10% Owner | Jul 30 '25 | Buy | 6.14 | 8,923 | 54,787 | 11,807,485 | Jul 31 |
| Griffiths Richard Ian | 10% Owner | Jul 29 '25 | Buy | 6.20 | 14,559 | 90,266 | 11,798,562 | Jul 31 |
| Griffiths Richard Ian | 10% Owner | Jul 22 '25 | Buy | 6.09 | 2,910 | 17,722 | 11,784,003 | Jul 23 |